Sharp Therapeutics Corp. (TSXV:SHRX)

Canada flag Canada · Delayed Price · Currency is CAD
3.950
-0.250 (-5.95%)
At close: Nov 18, 2025
79.55%
Market Cap118.54M
Revenue (ttm)n/a
Net Income (ttm)-4.63M
Shares Out30.01M
EPS (ttm)-0.15
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume500
Average Volume4,000
Open3.940
Previous Close4.200
Day's Range3.940 - 3.950
52-Week Range0.230 - 5.000
Beta-1.47
RSI54.25
Earnings DateNov 28, 2025

About Sharp Therapeutics

Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies, enables discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and Mine, a proprietary IP-protected analytics platform that captures all data for all AlloChem compounds in all CoreX assays. Sharp Therapeutics Corp. is headquartered in Pittsburgh, Pennsylvania. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Scott Sneddon
Country Canada
Stock Exchange TSX Venture Exchange
Ticker Symbol SHRX
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.